Floatz logo

Sibutramine

Binge Eating

Yale UniversitySmall moleculePhase 4 / ApprovedDormant
BBB
76/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
64/ 100
Competitive Position
95/ 100

Competitive context

3 Active assets in the Binge Eating cohort.

Asset / SponsorPhaseRating
Liraglutide
Universiti Kebangsaan Malaysia Medical Centre
Phase 4BB
Topamax
University of Virginia
Phase 3BB
Namenda
Mclean Hospital
Phase 4BB
Orlistat
Yale University
Phase 4BB
LAMOTRIGINE
Lindner Center of HOPE
Phase 3BB

View all 12 →

Same molecule, other indications

Sibutramine is also rated in:

hypertensive disorderDormant
BB
Indicative ·
71 / 100
View asset →
obesity disorderDormant
BB
Indicative ·
70 / 100
View asset →
polycystic ovary syndromeDormant
BB
Indicative ·
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →